| 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (NCT04743661) | Pediatric Brain Tumor Consortium | 2022-04-04 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888) | National Cancer Institute (NCI) | 2021-05-03 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer (NCT04521946) | M.D. Anderson Cancer Center | 2021-01-14 |
| Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children (NCT04501718) | Beijing Sanbo Brain Hospital | 2020-10-28 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults (NCT03893487) | Sabine Mueller, MD, PhD | 2019-08-07 |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors (NCT03598244) | National Cancer Institute (NCI) | 2018-11-27 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | National Cancer Institute (NCI) | 2018-11-14 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250) | National Cancer Institute (NCI) | 2018-08-13 |
| PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (NCT03299309) | Daniel Landi | 2018-06-29 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (NCT03213652) | National Cancer Institute (NCI) | 2018-04-17 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (NCT03434262) | St. Jude Children's Research Hospital | 2018-03-05 |
| Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors (NCT03387020) | Pediatric Brain Tumor Consortium | 2018-01-13 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678) | National Cancer Institute (NCI) | 2017-11-28 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (NCT03233204) | National Cancer Institute (NCI) | 2017-09-14 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704) | National Cancer Institute (NCI) | 2017-08-23 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620) | National Cancer Institute (NCI) | 2017-07-31 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (NCT02359565) | National Cancer Institute (NCI) | 2015-06-03 |
| Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors (NCT02271711) | M.D. Anderson Cancer Center | 2015-03-17 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT02095132) | National Cancer Institute (NCI) | 2014-03-28 |
| Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors (NCT01217437) | National Cancer Institute (NCI) | 2010-11-22 |
| Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors (NCT00983398) | OHSU Knight Cancer Institute | 2009-07-09 |